AFFiRiS AG
- Country
- 🇦🇹Austria
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.affiris.com
Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease
- Conditions
- Alzheimer´s Disease
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 11
- Registration Number
- NCT01357629
- Locations
- 🇦🇹
Studienzentrum der PROSENEX Ambulatoriumsbetriebs GmbH, Vienna, Austria
🇦🇹Univ. Klinik für Psychiatire und Psychotherapie, Wien, Austria
Safety and Tolerability of AFFITOPE AD03
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2011-12-20
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 28
- Registration Number
- NCT01309763
- Locations
- 🇦🇹
MUW Wien, Vienna, Austria
Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
- Conditions
- HDLDrug Safety
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 36
- Registration Number
- NCT01284582
- Locations
- 🇦🇹
Department for Clinical Pharmacology Medical University Vienna, Vienna, Austria
AD01 Follow up Extension Visit
- Conditions
- Alzheimer´s Disease
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 17
- Registration Number
- NCT01225809
- Locations
- 🇦🇹
Univ. Klinik für Neurologie, Wien, Austria
Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 335
- Registration Number
- NCT01117818
- Locations
- 🇦🇹
Landeskrankenhaus Hall Gedächtnisambulanz, Hall in Tirol, Austria
🇦🇹LNK Wagner-Jauregg, Dept. of geriatrics, Linz, Austria
🇦🇹Christian Doppler Klinik, Univ. Klinik f. Neurologie, Salzburg, Austria
Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 20
- Registration Number
- NCT01093664
- Locations
- 🇦🇹
Ordination Schmitz, Vienna, Austria
Long-term Safety and Tolerability of AFFITOPE AD01
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2008-07-08
- Last Posted Date
- 2010-05-27
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 22
- Registration Number
- NCT00711139
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Long-term Safety and Tolerability of AFFITOPE AD02
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2008-07-08
- Last Posted Date
- 2010-05-27
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 23
- Registration Number
- NCT00711321
- Locations
- 🇦🇹
Ordination Schmitz, Vienna, Austria
Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 24
- Registration Number
- NCT00633841
- Locations
- 🇦🇹
Ordination Univ. Doz. Dr. Margot Schmitz, Vienna, Austria
Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 24
- Registration Number
- NCT00495417
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria